Dr Eduardo Sotomayor speaks to ecancer about the advances in the management of patients with Hodgkin lymphoma and non-Hodgkin lymphoma.
He initially, talks about the main study from ASCO 2022 regarding the treatment of stage III and IV of Hodgkin lymphoma with a new antibody-drug conjugate.
Dr Sotomayor also discusses new combination therapies for patients with relapsed Hodgkin lymphoma. He further discusses bispecific antibodies for treating non-Hodgkin lymphoma.
He concludes by talking about the treatment strategies he uses to treat lymphoma patients.